Last updated on January 2019

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Lung Cancer


Brief description of study

The purpose of this research study is to see if Abraxane and Gemcitabine given together will be effective in treating small cell lung cancer that has progressed after one line of treatment.

Detailed Study Description

This study is designed as a second-line therapy for patients with histologically or cytologically confirmed small cell lung cancer. Eligible patients will receive Nab-Paclitaxel (Abraxane), 100 mg/m2, IV over 30 minutes on Days 1 and 8 of a 21-day cycle followed by Gemcitabine, 1000 mg/m2, IV over 30 minutes on Days 1 and 8 of a 21-day cycle. Subjects can continue receiving Nab-Paclitaxel and Gemcitabine until disease progression, unacceptable toxicity or withdrawal from the study. Tumor measurements will be done every 2 cycles.

Clinical Study Identifier: NCT02769832

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.